関節内補充療法用医療機器:企業動向

GlobalDataが発行した調査報告書(GDME1039FPR)
◆英語タイトル:Viscosupplementation - Current and Future Players
◆商品コード:GDME1039FPR
◆発行会社(リサーチ会社):GlobalData
◆発行日:2015年7月10日
◆ページ数: ※お問い合わせください。
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,385 ⇒換算¥608,505見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD8,300 ⇒換算¥937,900見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Viscosupplementation – Current and Future Players

Summary

Osteoarthritis (OA) constitutes a growing public health burden, and is the most common cause of musculoskeletal disability across the globe. Intra-articular viscosupplementation with hyaluronic acid (HA) has become an increasingly accepted therapeutic alternative to knee replacement surgery in the symptomatic management of OA over the past decade. Going forward, palliative pain treatments are likely to continue to fare well as healthcare reform kicks in and lag times for knee replacement become the norm. Growth of the viscosupplementation market will be highest in the US and the Asia-Pacific (APAC) region, where there is a significant pent-up demand for early intervention in the management of OA.
The increasing prevalence of OA and the lower cost of prescribing viscosupplementation compared with knee replacement surgery have prompted the medical community to take a closer look at this therapy. However, there is a growing concern among physicians that the updated American Academy of Orthopaedic Surgeons (AAOS) and Osteoarthritis Research Society International (OARSI) treatment guidelines for knee OA will result in increased insurance denials for viscosupplementation. Moving forward, industry consolidation and intense competition in the viscosupplementation arena will cause increasing numbers of companies to augment their research efforts to differentiate their products from the lower-end competitors. The motivation to incorporate the favorable properties of different agents into a more effective viscosupplementation product has led to the manipulation and development of next-generation HA formulations consisting of not only HAs, but also pharmaceuticals, such as corticosteroids.
*This is an on-demand report and will be delivered within 4 working days (excluding weekends) of the purchase.

Highlights

Key Questions Answered

- Because the most prevalent treatment regimen varies from region to region, the competitive landscape in the viscosupplementation space can be quite different across the geographies covered in this report. Who are the leading players in the viscosupplementation market in different countries?

Reasons to buy

- “What Do Physicians Think” quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.

【レポートの目次】

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Treatment Modalities Overview
3.1 Treatment Paradigm
3.1.1 Physical Therapies
3.1.2 Medications
3.1.3 Hyaluronic Acid Viscosupplementation
3.1.4 Surgical Intervention
4 Competitive Assessment
4.1 Major Viscosupplementation Products
4.1.1 Adant
4.1.2 Arthrum
4.1.3 Curavisc
4.1.4 Durolane
4.1.5 Euflexxa
4.1.6 Fermathron
4.1.7 Gel-One
4.1.8 Go-On
4.1.9 Hyalgan
4.1.10 Hyalubrix and HyalOne
4.1.11 Jonexa
4.1.12 NeoVisc
4.1.13 Orthovisc and Monovisc
4.1.14 Ostenil
4.1.15 Recosyn
4.1.16 RenehaVis
4.1.17 Supartz/ARTZ
4.1.18 Suplasyn
4.1.19 Suvenyl
4.1.20 Synocrom
4.1.21 Synolis V-A
4.1.22 Synovial
4.1.23 Synvisc and Synvisc-One
4.2 Other Viscosupplementation Products
5 Pipeline Products
5.1 Overview
5.2 Gel-Syn (IBSA Institut Biochimique S.A.)
5.3 Cingal (Anika Therapeutics)
5.4 Hydros-TA (Carbylan Therapeutics)
5.5 Additional Indication for Synvisc-One (Sanofi)
5.6 Hymovis (Fidia Farmaceutici S.p.A.)
5.7 HA-NSAID Conjugates (Seikagaku Corporation)
5.8 Additional Indication for Supartz/ARTZ (Seikagaku Corporation)
5.9 Clodronate-HA Conjugates (Abiogen Pharma)
6 Current and Future Players
6.1 Trends in Corporate Strategy
6.2 Major Manufacturers
6.2.1 Anika Therapeutics
6.2.2 Chugai Pharmaceutical
6.2.3 Ferring Pharmaceuticals
6.2.4 Fidia Farmaceutici S.p.A.
6.2.5 Meda AB
6.2.6 Sanofi
6.2.7 Seikagaku Corporation
6.3 Major Marketing Partners
6.3.1 Bioventus
6.3.2 DePuy Synthes
6.3.3 Zimmer-Biomet
7 Appendix
7.1 Bibliography
7.2 Abbreviations
7.3 Report Methodology
7.3.1 Overview
7.3.2 Coverage
7.3.3 Secondary Research
7.3.4 Forecasting Methodology
7.3.5 Primary Research — Key Opinion Leader Interviews
7.3.6 Expert Panel Validation
7.4 Physicians and Specialists Included in This Study
7.5 About the Authors
7.5.1 Analysts
7.5.2 Jim Coutcher, MS, Global Head of Healthcare
7.6 About MediPoint
7.7 About GlobalData
7.8 Contact Us
7.9 Disclaimer

1.1 List of Tables
Table 1: Product Profile - Adant
Table 2: Product Profile - Arthrum
Table 3: Product Profile - Curavisc
Table 4: Product Profile - Durolane
Table 5: Product Profile - Euflexxa
Table 6: Product Profile - Fermathron
Table 7: Product Profile - Gel-One
Table 8: Product Profile - Go-On
Table 9: Product Profile - Hyalgan
Table 10: Product Profile - Hyalubrix and HyalOne
Table 11: Product Profile - Jonexa
Table 12: Product Profile - NeoVisc
Table 13: Product Profile - Orthovisc and Monovisc
Table 14: Product Profile - Ostenil
Table 15: Product Profile - Recosyn
Table 16: Product Profile - RenehaVis
Table 17: Product Profile - Supartz/ARTZ
Table 18: Product Profile - Suplasyn
Table 19: Product Profile - Suvenyl
Table 20: Product Profile - Synocrom
Table 21: Product Profile - Synolis V-A
Table 22: Product Profile - Synovial
Table 23: Product Profile - Synvisc and Synvisc-One
Table 24: Other Viscosupplementation Products in the Global Market, 2015
Table 25: Major Pipeline Products in the Viscosupplementation Market, 2015
Table 26: Company Profile - Anika Therapeutics
Table 27: Anika Therapeutics’ Viscosupplementation Portfolio Assessment, 2015
Table 28: SWOT Analysis - Anika Therapeutics
Table 29: Company Profile - Chugai Pharmaceutical
Table 30: Chugai Pharmaceutical’s Viscosupplementation Portfolio Assessment, 2015
Table 31: SWOT Analysis - Chugai Pharmaceutical
Table 32: Company Profile - Ferring Pharmaceuticals
Table 33: Ferring Pharmaceutical’s Viscosupplementation Portfolio Assessment, 2015
Table 34: SWOT Analysis - Ferring Pharmaceuticals
Table 35: Company Profile - Fidia Farmaceutici S.p.A.
Table 36: Fidia Farmaceutici S.p.A.’s Viscosupplementation Portfolio Assessment, 2015
Table 37: SWOT Analysis - Fidia Farmaceutici S.p.A.
Table 38: Company Profile - Meda AB
Table 39: Meda AB’s Viscosupplementation Portfolio Assessment, 2015
Table 40: SWOT Analysis - Meda AB
Table 41: Company Profile - Sanofi
Table 42: Sanofi’s Viscosupplementation Portfolio Assessment, 2015
Table 43: SWOT Analysis - Sanofi
Table 44: Company Profile - Seikagaku Corporation
Table 45: Seikagaku Corporation’s Viscosupplementation Portfolio Assessment, 2015
Table 46: SWOT Analysis - Seikagaku Corporation
Table 47: Company Profile - Bioventus
Table 48: Bioventus’ Viscosupplementation Portfolio Assessment, 2015
Table 49: SWOT Analysis - Bioventus
Table 50: Company Profile - DePuy Synthes
Table 51: DePuy Synthes’ Viscosupplementation Portfolio Assessment, 2015
Table 52: SWOT Analysis - DePuy Synthes
Table 53: Company Profile - Zimmer-Biomet
Table 54: Zimmer-Biomet’s Viscosupplementation Portfolio Assessment, 2015
Table 55: SWOT Analysis - Zimmer-Biomet



【掲載企業】

Anika Therapeutics
Chugai Pharmaceutical
Ferring Pharmaceuticals
Fidia Farmaceutici S.p.A.
Meda AB
Sanofi
Seikagaku Corporation
Bioventus
DePuy Synthes
Zimmer-Biomet

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 関節内補充療法用医療機器:企業動向(Viscosupplementation - Current and Future Players)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆